Postoperative radiotherapy to stabilize a tumor embolus in clear cell renal cell carcinoma: A case report
- Authors:
- Zhi-Hua Gong
- Lv-Jun Yan
- Jian-Guo Sun
View Affiliations
Affiliations: Department of Oncology, Cancer Institute of People's Liberation Army, Xinqiao Hospital, Third Military Medical University, Chongqing 400037, P.R. China
- Published online on: August 5, 2014 https://doi.org/10.3892/ol.2014.2421
-
Pages:
1856-1858
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Abstract
Superior vena cava (SVC) syndrome results from clear cell renal cell carcinoma and is a challenge in clinical practice due to its pathological complexity and a lack of research data. The current study presents a 49‑year‑old female with symptoms of exertional dyspnea and increased fatigue, which had persisted for 15 months, as well as bilateral edema in the lower limbs for two days. A transesophageal echocardiogram demonstrated a right atrial mass originating from the inferior vena cava (IVC; size, 14x8 cm) that caused a tricuspid inflow obstruction. Following a partial resection of the thrombus, a clear cell renal cell carcinoma was identified by histological examination. The patient received intensity‑modulated radiation therapy following refusal of other therapeutic methods. The eleven‑month follow‑up indicated that the tumor on the kidney and IVC was stable. Intensity‑modulated radiation therapy may be beneficial to patients with clear cell renal cell carcinoma and SVC syndrome. However, additional studies are required to obtain further data regarding the treatment of this syndrome.
View References
|
1
|
Wilson LD, Detterbeck FC and Yahalom J:
Clinical practice. Superior vena cava syndrome with malignant
causes. N Engl J Med. 356:1862–1869. 2007.
|
|
2
|
Rowell NP and Gleeson FV: Steroids,
radiotherapy, chemotherapy and stents for superior vena caval
obstruction in carcinoma of the bronchus. Cochrane Database Syst
Rev. 4:CD0013162001.
|
|
3
|
Urruticoechea A, Mesía R, Domínguez J, et
al: Treatment of malignant superior vena cava syndrome by
endovascular stent insertion. Experience on 52 patients with lung
cancer. Lung Cancer. 43:209–214. 2004.
|
|
4
|
Kennedy DP and Palit TK: Reconstruction of
superior vena cava syndrome due to benign disease using superficial
femoral vein. Ann Vasc Surg. 24:555.e7–555.e12. 2010.
|
|
5
|
Lequaglie C, Conti B, Brega-Massone PP and
Giudice G: The difficultapproach to neoplastic superior vena cava
syndrome: surgical option. J Cardiovasc Surg (Torino). 44:667–671.
2003.
|
|
6
|
Svedman C, Sandström P, Pisa P, et al: A
prospective Phase II trial of using extracranial stereotactic
radiotherapy in primary and metastatic renal cell carcinoma. Acta
Oncol. 45:870–875. 2006.
|
|
7
|
Samlowski WE, Majer M, Boucher KM, et al:
Multidisciplinary treatment of brain metastases derived from clear
cell renal cancer incorporating stereotactic radiosurgery. Cancer.
113:2539–2548. 2008.
|
|
8
|
Chiba H, Hirose T, Shimoda N and Kanagawa
K: A case of advanced renal cell carcinoma with inferior vena cava
thrombus treated with sunitinib as neoadjuvant therapy. Nihon
Hinyokika Gakkai Zasshi. 103:623–626. 2012.(In Japanese).
|
|
9
|
Harshman LC, Srinivas S, Kamaya A and
Chung BI: Laparoscopicradical nephrectomy after shrinkage of a
caval tumor thrombus with sunitinib. Nat Rev Urol. 6:338–343.
2009.
|
|
10
|
Cost NG, Delacroix SE Jr, Sleeper JP, et
al: The impact of targeted molecular therapies on the level of
renal cell carcinoma vena caval tumor thrombus. Eur Urol.
59:912–918. 2011.
|
|
11
|
Bigot P, Fardoun T, Bernhard JC, et al:
Neoadjuvant targeted molecular therapies in patients undergoing
nephrectomy and inferior vena cava thrombectomy: is it useful?
World J Urol. 32:109–114. 2014.
|
